Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

NCT05878314 · clinicaltrials.gov ↗

RECRUITING

Status

504

Enrollment

OTHER

Sponsor class

Conditions

Hormone Receptor Positive HER-2 Negative Breast Cancer

Sponsor

University Hospital Tuebingen

Collaborators

[object Object]
[object Object]